ClinicalTrials.gg
Active, not recruitingNCT04888754CHRONOUpdated Feb 13, 2024

A Prospective Cohort for ex Vivo Cure Studies With Chronic HIV Infected Patients in the Netherlands

An observational study in HIV Infections, HIV-1-infection and HIV-2 Infection, sponsored by Erasmus Medical Center. Active, not recruiting at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-13.

Sponsored by Erasmus Medical Center · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
35
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 86 studies in HIV Infections with a site in Netherlands — 6 open to participants now, 10 under way, 2 of them phase 3. HIV Infections · Netherlands.

Enrollment
9th of 10
35 · median 330
Started
2021
with 2 others
Observational
10 of 86
3 open now
Registered
77th of 86
by date
Lead sponsor
5 of 86
Erasmus Medical Center

Among the 86 studies in HIV Infections with a site in Netherlands, this one is the 9th largest by enrollment of the 10 observational ones that give a count, is one of 3 that started in 2021, is one of 10 observational ones, and was the 77th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

6 of the 86 studies in HIV Infections with a site in Netherlands are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 86 studies in HIV Infections with a site in Netherlands, or all of them as a file.
02

Study summary

A prospective non-interventional cohort study at Erasmus MC of adult chronic HIV infected patients of ≥18 years of age who initiate antiretroviral therapy in routine care.

Read the detailed description

HIV cannot be cured with the current treatment armamentarium. A reservoir of latently HIV infected long lived CD4+T-cells is present in patients with HIV that are not affected by antiretroviral therapy. The evolution of this reservoir after therapy initiation is ill understood, as are the potential strategies to eradicate this reservoir. This study aims to anticipate on future HIV cure strategies by building a cohort to study ex vivo the reservoirs of HIV patients, the obstacles to cure HIV, and new therapeutic compounds and strategies.

Main study parameters/endpoints:

  1. Change in viral reservoir size after antiretroviral treatment initiation.
  2. Evolution of phenotypical and functional aspects of the anti-HIV host immune responses.
  3. Ex vivo activity of established and novel HIV latency reversing agents.
  4. Variance in HIV reservoir and host immunity between HIV subtypes and clinical variables.

A project from the Erasmus MC HIV Eradication Group (EHEG).

03

Conditions studied

  • HIV Infections
  • HIV-1-infection
  • HIV-2 Infection

Browse trials for

Keywords

  • HIV
  • HIV cure
  • HIV reservoir
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients are 18 years or older with a confirmed HIV infection without prior exposure to cART (treatment naïve). Prior use of pre-exposure prophylaxis is allowed.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age >18 years.
  • Confirmed -1 or HIV-2 infection
  • Judged willing to initiate and adhere to cART by the HIV physician.

Exclusion criteria

Exclusion Criteria:

  • Inability to place venous catheters to draw blood.
  • Major comorbidities:

    1. Severe symptomatic anemia or recent symptomatic cardiovascular event (un-stable angina pectoris, decompensated heart failure, myocardial infarction).
    2. The inability to participate due to any other relevant social, environmental,psychological, factors or according to the treating physician's judgement.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
35 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. To develop a prospective cohort in the Netherlands of chronic HIV infected patients within-depth reservoir characterization for future cure interventions.

    The HIV latent reservoir will be characterised in chronic HIV patients using novel techniques like FISH-flow

    Time frame: 5-10 years

  2. To study the evolution of the HIV reservoir and immune host responses over time during antiretroviral therapy.

    The HIV reservoir will be characterised over time to study the dynamics of the reservoir

    Time frame: 5-10 years

Secondary outcomes

  1. To explore established and putative new interventions aimed at curing HIV.

    Blood and leucapheresis samples will be collected for testing of HIV cure drugs

    Time frame: 5-10 years

  2. To explore differences in reservoir size, activity and host responses, and their relation with clinical characteristics, between patients with different dominant HIV subtypes and sexes.

    Blood and leucapheresis samples will be collected for reservoir characterisation to compare reservoirs between patients

    Time frame: 5-10 years

  3. To compare and validate new reservoir assays with current established assays.

    Blood and leucapheresis samples will be collected to compare and validate new reservoir assays

    Time frame: 5-10 years

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided — No definitive decision on this yet. This will also depend on confidentiality.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2021 (actual). Primary completion is estimated for Jan 2027, 68 months after the start.

Of 187 non-industry observational studies under HIV Infections, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 69. This study's planned 68 months is above that.

Counting every sponsor, half of 201 studies reached it within 38 months; a quarter within 16 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2021
First posted
May 17, 2021
StartActual
May 26, 2021
Primary completionEst.
Jan 2027
CompletionEst.
Jan 2034
Last update
Feb 13, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04888754
Responsible party
Casper Rokx (Principal Investigator, Erasmus Medical Center) — Principal investigator
First posted
May 17, 2021
Start date
May 26, 2021
Primary completion
Jan 2027 (estimated)
Completion
Jan 2034 (estimated)
Last update
Feb 13, 2024

Study contacts

Casper Rokx, MD PhD
principal investigator · Erasmus Medical Center
Tokameh Mahmoudi, PhD
principal investigator · Erasmus Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion